Colonial Trust Advisors lifted its position in Pfizer Inc. (NYSE:PFE) by 77.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,661 shares of the biopharmaceutical company’s stock after buying an additional 16,833 shares during the quarter. Colonial Trust Advisors’ holdings in Pfizer were worth $1,419,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in PFE. NewSquare Capital LLC lifted its holdings in shares of Pfizer by 0.4% during the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock worth $1,976,000 after buying an additional 266 shares in the last quarter. Northwest Wealth Management LLC lifted its holdings in shares of Pfizer by 2.4% during the third quarter. Northwest Wealth Management LLC now owns 11,311 shares of the biopharmaceutical company’s stock worth $415,000 after buying an additional 268 shares in the last quarter. Aevitas Wealth Management Inc. lifted its holdings in shares of Pfizer by 1.7% during the second quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock worth $520,000 after buying an additional 269 shares in the last quarter. Cutter & CO Brokerage Inc. lifted its holdings in shares of Pfizer by 2.0% during the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 274 shares in the last quarter. Finally, Beaumont Asset Management L.L.C. lifted its holdings in shares of Pfizer by 1.3% during the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock worth $694,000 after buying an additional 276 shares in the last quarter. 69.08% of the stock is owned by institutional investors and hedge funds.
Shares of PFE stock opened at $35.28 on Friday. The business’s 50 day simple moving average is $36.74 and its 200 day simple moving average is $36.59. Pfizer Inc. has a one year low of $27.88 and a one year high of $40.97. The stock has a market capitalization of $196.05 billion, a PE ratio of 14.00, a PEG ratio of 3.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.01. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business had revenue of $12.13 billion for the quarter, compared to analysts’ expectations of $12.30 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The firm’s revenue was down 4.3% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be paid a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.31%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
In other news, Director Ronald E. Blaylock bought 13,000 shares of the stock in a transaction dated Thursday, August 6th. The shares were bought at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 1,200,000 shares of the stock in a transaction dated Tuesday, October 27th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $12,000,000.00. Following the completion of the transaction, the insider now directly owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The disclosure for this purchase can be found here. 0.08% of the stock is currently owned by insiders.
A number of equities research analysts have recently weighed in on PFE shares. Berenberg Bank assumed coverage on Pfizer in a report on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price for the company. Truist assumed coverage on Pfizer in a research note on Friday, October 23rd. They issued a “buy” rating and a $42.00 price target for the company. Royal Bank of Canada set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Friday, October 16th. Atlantic Securities downgraded Pfizer from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Finally, SVB Leerink lifted their target price on Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus price target of $39.66.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: High-Yield Dividend Stocks
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.